KBC Group
PCVX icon

KBC Group’s Vaxcyte PCVX Stock Holding History

KBC Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$227K Hold
3,898
– – ﹤0.01% 937
2025
Q4 		$180K Hold
3,898
– – ﹤0.01% 959
2025
Q3 		$140K Hold
3,898
– – ﹤0.01% 1074
2025
Q2 		$127K Sell
3,898
-884
-18% -$29K ﹤0.01% 1068
2025
Q1 		$181K Buy
4,782
+7
+0.1% +$560 ﹤0.01% 1140
2024
Q4 		$391K Buy
4,775
+2,092
+78% +$208K ﹤0.01% 858
2024
Q3 		$307K Buy
2,683
+322
+14% +$29K ﹤0.01% 790
2024
Q2 		$178K Buy
2,361
+351
+17% +$23.9K ﹤0.01% 904
2024
Q1 		$137K Buy
2,010
+472
+31% +$32.7K ﹤0.01% 986
2023
Q4 		$97K Hold
1,538
– – ﹤0.01% 1080
2023
Q3 		$78K Buy
+1,538
New +$75.9K ﹤0.01% 1123

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's PCVX Position: Q1 2026 in Review

KBC Group held its Vaxcyte (PCVX) position steady in Q1 2026 at 3,898 shares worth $227K. The position accounts for ﹤0.01% of the portfolio, ranked #937.

KBC Group first reported a position in PCVX in Q3 2023 and has held it in 11 quarters since. The position peaked at $391K in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • KBC Group held 3,898 shares of Vaxcyte worth $227K as of Q1 2026.
  • KBC Group left its Vaxcyte share count unchanged in Q1 2026.
  • Vaxcyte made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #937 holding.
  • KBC Group first reported a position in Vaxcyte in Q3 2023 and has held it in 11 quarters since.
  • KBC Group's Vaxcyte position peaked at $391K in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.